• Technical Name
  • 百發百中、相醫維命 – 發展伴隨式診斷以進行小分子RNA干擾片段的癌症精準醫療
  • Operator
  • National Cheng Kung University
  • Booth
  • 精準健康(生技&新藥) Precision Health(Biotech & New Drug Development)
  • Contact
  • 洪良宜
  • Email
  • lyhung@mail.ncku.edu.tw
Technical Description Cancer is the first leading cause of death in Taiwan. Targeted therapy allows the cancer cells to be specifically targeted, reduces the side effects,achieves the purpose of precision cancer treatment. This report contains two invention technologies which combined early & specific diagnosis of a specific Aurora-A mRNA isoform in cancers (the companion diagnosis)the treated with a selective locked nucleic acid (LNA)-modified novel double-stranded short interfering nucleic acid (siRNA) to inhibit the translation of this Aurora-A mRNA isoform (targeted therapy) in cancers.
Scientific Breakthrough In the past 20 years, small molecule inhibitors have been used to inhibit the overexpressed Aurora-A in cancers however, those inhibitors lack specificitymay cause serious side effects. The specificnovel double-stranded short interfering nucleic acid (siRNA) was designed according to the computer simulated RNA structure of the specific Aurora-A mRNA 5’-UTR isoform.The probes used for companion diagnosis was synthesized using an overlapping coverage strategy to increase the specificitysensitivity for detecting the expression of the specific Aurora-A mRNA 5’-UTR isoform.
Industrial Applicability This invention is a LNA-modified siRNA which can selectively inhibit the translation of a specific Aurora-A mRNA isoform (targeted therapy) in a variety of cancers. This is a patent protective siRNA with excellent anti-cancer ability it has the potential to become anti-cancer drugapply to cancer therapy. The probe chip can detect the tumor-specific Aurora-A mRNA isoform it’s function is the companion diagnosis for treating Aurora-A mRNA isoform selective siRNA drug in a variety of cancers. In addition, this chip can also be used to early detect the precancerous lesions.